Pfizer Hones Biosimilars Approach For Individual Countries

The company has biosimilars of Rituxan, Herceptin and Remicade in clinical trials and a biosimilar to Humira is about to enter Phase I; Pfizer is pursuing the biosimilar pathway for all of its candidates.